MAM
AMPH icon

Martingale Asset Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Martingale Asset Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,400
Closed -$332K – 798
2025
Q4 		$332K Sell
12,400
-6,121
-33% -$158K 0.01% 676
2025
Q3 		$494K Sell
18,521
-6,021
-25% -$155K 0.01% 615
2025
Q2 		$563K Hold
24,542
– – 0.01% 597
2025
Q1 		$711K Sell
24,542
-15,663
-39% -$500K 0.02% 536
2024
Q4 		$1.49M Sell
40,205
-60
-0.1% -$2.74K 0.04% 380
2024
Q3 		$1.95M Buy
40,265
+1,000
+3% +$43.9K 0.04% 321
2024
Q2 		$1.57M Sell
39,265
-8
-0% -$332 0.03% 353
2024
Q1 		$1.72M Hold
39,273
– – 0.03% 334
2023
Q4 		$2.43M Sell
39,273
-508
-1% -$26.7K 0.05% 244
2023
Q3 		$1.83M Sell
39,781
-1,782
-4% -$97.2K 0.04% 288
2023
Q2 		$2.39M Sell
41,563
-605
-1% -$26.8K 0.05% 238
2023
Q1 		$1.58M Sell
42,168
-3,980
-9% -$130K 0.03% 326
2022
Q4 		$1.29M Sell
46,148
-19,388
-30% -$563K 0.03% 387
2022
Q3 		$1.84M Sell
65,536
-9,038
-12% -$295K 0.04% 267
2022
Q2 		$2.6M Sell
74,574
-8,562
-10% -$306K 0.05% 226
2022
Q1 		$2.99M Sell
83,136
-18,866
-18% -$535K 0.04% 213
2021
Q4 		$2.38M Sell
102,002
-7,985
-7% -$163K 0.03% 268
2021
Q3 		$2.09M Buy
109,987
+60,570
+123% +$1.19M 0.03% 290
2021
Q2 		$997K Buy
49,417
+30,000
+155% +$565K 0.01% 398
2021
Q1 		$357K Sell
19,417
-300
-2% -$5.58K ﹤0.01% 705
2020
Q4 		$398K Sell
19,717
-82,800
-81% -$1.61M ﹤0.01% 670
2020
Q3 		$1.92M Sell
102,517
-110,313
-52% -$2.22M 0.02% 429
2020
Q2 		$4.78M Buy
212,830
+13
+0% +$238 0.06% 318
2020
Q1 		$3.16M Buy
212,817
+3,179
+2% +$55.3K 0.04% 394
2019
Q4 		$4.04M Sell
209,638
-4,806
-2% -$92.2K 0.04% 437
2019
Q3 		$4.25M Buy
214,444
+13,706
+7% +$285K 0.04% 419
2019
Q2 		$4.24M Sell
200,738
-19,700
-9% -$412K 0.04% 415
2019
Q1 		$4.5M Buy
220,438
+16,692
+8% +$374K 0.05% 388
2018
Q4 		$4.05M Buy
203,746
+98,117
+93% +$1.93M 0.05% 369
2018
Q3 		$2.03M Buy
+105,629
New +$1.88M 0.02% 549
2016
Q4 		– Sell
-72,903
Closed -$1.38M – 958
2016
Q3 		$1.38M Buy
72,903
+8,203
+13% +$149K 0.02% 604
2016
Q2 		$1.04M Sell
64,700
-25,525
-28% -$360K 0.02% 488
2016
Q1 		$1.08M Hold
90,225
– – 0.02% 469
2015
Q4 		$1.28M Sell
90,225
-1,597
-2% -$21.1K 0.03% 404
2015
Q3 		$1.07M Buy
91,822
+63,513
+224% +$953K 0.03% 454
2015
Q2 		$498K Buy
+28,309
New +$441K 0.01% 692

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Martingale Asset Management's AMPH Position: Q1 2026 in Review

Martingale Asset Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 12,400 shares — an estimated $332K sold.

Martingale Asset Management first reported a position in AMPH in Q2 2015 and held it in 36 quarters. The position peaked at $4.78M in Q2 2020. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Martingale Asset Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Martingale Asset Management sold 12,400 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $332K.
  • Martingale Asset Management first reported a position in Amphastar Pharmaceuticals in Q2 2015 and held it in 36 quarters.
  • Martingale Asset Management's Amphastar Pharmaceuticals position peaked at $4.78M in Q2 2020.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.